<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00274261</url>
  </required_header>
  <id_info>
    <org_study_id>CCN004</org_study_id>
    <secondary_id>HHSN2752004033661</secondary_id>
    <nct_id>NCT00274261</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®</brief_title>
  <official_title>A Phase II/III Multicenter, Randomized, Double-masked, Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Decisions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Health Decisions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-masked, controlled, phase III study of repeated use
      of C31G vaginal gel compared to Conceptrol® Vaginal Gel as the primary method of
      contraception over six months (183 days) and at least six cycles of use. In addition, there
      is an opportunity for subjects to continue with study treatment for up to twelve months (365
      days) and twelve cycles of treatment upon completion of the first six months of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 85% of American women (52 million) between the ages of 15 and 44 are sexually
      active . Approximately two-thirds or 38 million women use some form of birth control and/or
      STD prevention. With growing awareness of the risk of STDs, increasing numbers of women will
      require contraceptive methods that provide protection against STDs in addition to providing
      the basic contraceptive function. Currently there is no single, reasonably effective method
      to achieve both ends. Condoms, both male and female, present problems of acceptability for
      the partners of many at-risk women and, thus, cannot be considered an effective contraceptive
      and STD preventive for many people. A spermicide that also has the ability to prevent
      transmission of STDs would be a major advance, and of tremendous value to women worldwide.

      C31G is an effective spermicide with in vitro activity equal to that of N-9 . C31G has been
      found to be a broad-spectrum antibacterial agent in vitro or in animals, active against both
      gram-positive and gram-negative organisms, including chlamydia, and a range of antibiotic
      resistant strains. It is also active against enveloped viruses including HIV and HSV. Thus,
      the primary objective of the study is to determine the contraceptive efficacy of C31G vaginal
      gel compared to Conceptrol® Vaginal Gel. The secondary objectives are to determine the safety
      and acceptability of the compounds with use over a period of six months or twelve months.
      Additional evaluations include the incidence of urinary tract infections (UTI), bacterial
      vaginosis (BV) and yeast vaginitis following the use of C31G vaginal gel compared to
      Conceptrol® Vaginal Gel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Cumulative Probability of Typical-use 6 Month (183 Days) Pregnancy.</measure>
    <time_frame>6 months</time_frame>
    <description>Number of pregnancies in women using C31G gel for 6 months (183 days) compared to women using Conceptrol gel for the same time frame.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events.</measure>
    <time_frame>duration of the study - through 6 month or 12 months of use</time_frame>
    <description>Evaluated by comparing the incidence of Adverse Events (AEs) among subjects using their assigned treatment for at least one day.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1565</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C31G</intervention_name>
    <description>The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nonoxynol-9 (N-9)</intervention_name>
    <description>The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Potential subjects must:

          -  Be healthy women, who are sexually active, at risk for pregnancy and desiring
             contraception.

          -  Be within the age range of 18 through 40 years inclusive.

          -  Be at low-risk for human immunodeficiency virus (HIV) or sexually transmitted disease
             (STD) infection and currently have a single sex partner (minimum 4 months) who is also
             at low-risk for HIV or STD.

          -  Have a negative urine pregnancy test prior to enrollment.

          -  Have normal cyclic menses with a usual length of 24 to 35 days over the last 2 cycles
             or at least one spontaneous, normal menstrual cycle (2 menses) since delivery,
             abortion, or after discontinuing hormonal contraception/hormonal therapy.

          -  Be willing to accept a risk of pregnancy.

          -  Be willing to engage in at least 4 acts of heterosexual vaginal intercourse per month
             for a period of 6 months.

          -  Be willing to be randomized to either study treatment.

          -  Be willing to only use the study product as the primary method of contraception over
             the course of the study with the exception of emergency contraception (EC), when
             indicated.

          -  Be capable of using the study product properly and agree to observe all study
             directions and requirements.

          -  Be willing to keep a diary to record coital information, product use information,
             information about the use of other vaginal products, and sign and symptom data of
             subject and partner.

          -  Agree not to participate in any other clinical trials during the course of the study.

          -  Be willing to give written informed consent to participate in the trial.

        Exclusion Criteria:

        Potential subjects must not:

          -  Have a history of allergy or sensitivity to spermicides or products containing N-9.

          -  Have had 3 or more urinary tract infections (UTI) in the past year.

          -  Have UTI by urine culture or symptomatic yeast vaginitis or symptomatic bacterial
             vaginosis diagnosed by wet mount unless treated and proof of cure is documented.

          -  Be pregnant, have a suspected pregnancy or desire to become pregnant during the course
             of the study.

          -  Have a history of infertility or of conditions that may lead to infertility, without
             subsequent intrauterine pregnancy.

          -  Have any contraindications to pregnancy (medical condition) or chronic use of category
             D or X medications.

          -  Have had more than one sexual partner in the last 4 months.

          -  Have shared injection drug needles within the past 12 months.

          -  Have or have been suspected to have HIV infection.

          -  Have been diagnosed with genital herpes simplex virus (HSV), with the first occurrence
             (initial episode) within three months prior to screening.

          -  Have 3 or more outbreaks of HSV within the last year.

          -  Have been diagnosed with any other STDs (including trichomonas) in the 6 months prior
             to the screening visit (with the exception of Human Papilloma Virus [HPV]).

          -  Be lactating or breastfeeding.

          -  Have any clinically significant abnormal vaginal bleeding or spotting within the month
             prior to screening.

          -  Have any clinically significant abnormal finding on pelvic examination or baseline
             labs, which in the view of the investigator, precludes her from participating in the
             trial.

          -  Have clinically significant signs of vaginal or cervical irritation on pelvic
             examination.

          -  Have had vaginal or cervical biopsy or vaginal surgery within 3 months prior to
             screening.

          -  Have used vaginal or systemic antibiotics or antifungals within 14 days prior to
             screening or randomization.

          -  Have had a Depo-Provera® injection in the 10 months prior to enrollment.

          -  Have an abnormal Pap smear with high grade squamous intraepithelial lesion (HSIL),
             atypical glandular cells (AGC) or ASC-H (atypical squamous cells, cannot exclude HSIL)
             within the last 12 months.

          -  Have an abnormal Pap smear with low-grade squamous intraepithelial lesion (LSIL) or
             ASCUS-HPV HR positive unless resolved by colposcopy.

          -  Have a Cervical Intraepithelial Neoplasia (CIN) diagnosis by biopsy within the last 12
             months.

          -  Have a history or a current diagnosis of cervical cancer.

          -  Consume (on average) greater than three drinks of an alcoholic beverage per day.

          -  Have a past history (within twelve months) or current history of drug abuse
             [recreational, prescription or over-the-counter (OTC)].

          -  Have taken an investigational drug or used an investigational device within the past
             30 days.

          -  Have previously participated in or completed this study or any other phase III study
             of C31G.

          -  Have issues or concerns (in the judgment of the investigator) that may compromise the
             safety of the subject or confound the reliability of compliance and information
             acquired in this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana L Blithe, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Family Health Council</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Family Health Council</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado - Advanced reproductive Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay State Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland MacDonald Women's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University College of Medicine</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.T. Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jones Institute of Reproductive Medicine, EVMS</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2006</study_first_submitted>
  <study_first_submitted_qc>January 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2006</study_first_posted>
  <results_first_submitted>December 14, 2012</results_first_submitted>
  <results_first_submitted_qc>April 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2013</results_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Nonoxynol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Female subjects were screened and enrolled at 15 sites in the US.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>C31G</title>
          <description>C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel</description>
        </group>
        <group group_id="P2">
          <title>Conceptrol</title>
          <description>Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5mL volume of gel.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="932"/>
                <participants group_id="P2" count="633"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="443"/>
                <participants group_id="P2" count="296"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="489"/>
                <participants group_id="P2" count="337"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>C31G</title>
          <description>C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel</description>
        </group>
        <group group_id="B2">
          <title>Conceptrol</title>
          <description>Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5mL volume of gel.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="932"/>
            <count group_id="B2" value="633"/>
            <count group_id="B3" value="1565"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="932"/>
                    <measurement group_id="B2" value="633"/>
                    <measurement group_id="B3" value="1565"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="5.58"/>
                    <measurement group_id="B2" value="28.3" spread="5.90"/>
                    <measurement group_id="B3" value="28.2" spread="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="932"/>
                    <measurement group_id="B2" value="633"/>
                    <measurement group_id="B3" value="1565"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="932"/>
                    <measurement group_id="B2" value="633"/>
                    <measurement group_id="B3" value="1565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Cumulative Probability of Typical-use 6 Month (183 Days) Pregnancy.</title>
        <description>Number of pregnancies in women using C31G gel for 6 months (183 days) compared to women using Conceptrol gel for the same time frame.</description>
        <time_frame>6 months</time_frame>
        <population>Modified Intent-To-Treat (MITT): ITT subjects whose diaries indicated they had at least one episode of coitus while using the assigned study product (also referred as “Typical-Use”) and for whom there is at least one report of pregnancy status.</population>
        <group_list>
          <group group_id="O1">
            <title>C31G</title>
            <description>C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel</description>
          </group>
          <group group_id="O2">
            <title>Conceptrol</title>
            <description>Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5mL volume of gel.</description>
          </group>
        </group_list>
        <measure>
          <title>The Cumulative Probability of Typical-use 6 Month (183 Days) Pregnancy.</title>
          <description>Number of pregnancies in women using C31G gel for 6 months (183 days) compared to women using Conceptrol gel for the same time frame.</description>
          <population>Modified Intent-To-Treat (MITT): ITT subjects whose diaries indicated they had at least one episode of coitus while using the assigned study product (also referred as “Typical-Use”) and for whom there is at least one report of pregnancy status.</population>
          <units>6 month probability of pregnancy</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="827"/>
                <count group_id="O2" value="555"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.093" upper_limit="0.147"/>
                    <measurement group_id="O2" value="0.12" lower_limit="0.087" upper_limit="0.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events.</title>
        <description>Evaluated by comparing the incidence of Adverse Events (AEs) among subjects using their assigned treatment for at least one day.</description>
        <time_frame>duration of the study - through 6 month or 12 months of use</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C31G Vaginal Gel</title>
            <description>C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel
C31G: The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.</description>
          </group>
          <group group_id="O2">
            <title>Conceptrol® Vaginal Gel</title>
            <description>Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
nonoxynol-9 (N-9): The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events.</title>
          <description>Evaluated by comparing the incidence of Adverse Events (AEs) among subjects using their assigned treatment for at least one day.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="932"/>
                <count group_id="O2" value="633"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="617"/>
                    <measurement group_id="O2" value="434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The overall safety population includes only subjects that actually used the product at least once totalling 1396.</desc>
      <group_list>
        <group group_id="E1">
          <title>C31G</title>
          <description>C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel</description>
        </group>
        <group group_id="E2">
          <title>Conceptrol</title>
          <description>Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5mL volume of gel.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="836"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="836"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="836"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Gastroenteritis escherichia coli</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="836"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="836"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="836"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Dermoid Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst Ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="836"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="836"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="836"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Stress incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="836"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="836"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="836"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="617" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="434" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharygitis</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Vaginal mycosis</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Smear cervix abnormal</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Menstrual cycle prolonged</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Genital pruritus female</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Oligomenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Vaginal burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Vaginal odor</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="836"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jason Woo, MD, MPH</name_or_title>
      <organization>NICHD</organization>
      <phone>301-496-1662</phone>
      <email>woojj@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

